Ricoh Partners with ERS Genomics for CRISPR/Cas9 License Agreement
Ricoh Company, Ltd. has entered into a significant non-exclusive licensing agreement with ERS Genomics Limited, granting access to foundational CRISPR/Cas9 genome editing technology patents in the USA and Japan. This collaboration underscores the importance of CRISPR/Cas9 as a breakthrough gene-editing tool , facilitating precise modification of targeted genome sequences essential for various applications, particularly in drug discovery research. CRISPR/Cas9 Genome Editing License Agreement The agreement follows Ricoh’s acquisition of Elixirgen Scientific, Inc. in 2022, a company renowned for its expertise in rapid and efficient differentiation of human induced pluripotent stem (iPS) cells and mRNA design, production, and management. By combining these core technologies with CRISPR/Cas9 genome editing, Ricoh aims to revolutionize drug discovery by predicting drug mechanisms and enhancing the speed and efficiency of mRNA design. Ricoh’s integration of Elixirgen Scientific’s techno...